GlassScriptPhysician profile
Kenneth R Mayer
NPI 1669449229
$8,882.53
in general payments reported to CMS, 2019-2025
46 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $1,530 · 2021: $1,199 · 2022: $1,230 · 2023: $1,057 · 2024: $1,176 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.58 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $857.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $788.99 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $623.54 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novo Nordisk INC | $622.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $559.96 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $497.37 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $468.53 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $381.89 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $359.04 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.34 | 2019-2024 | Trintellix |
| Dexcom, INC. | $236.79 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $229.35 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $189.57 | 2019-2023 | |
| Allergan, INC. | $173.32 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.